Education
About Us
Working with TipRanks
Follow Us
Nucana Plc (NCNA)
NASDAQ:NCNA
NCNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.78 - $446.00
Previous CloseN/A
Volume88.96K
Average Volume (3M)393.93K
Market Cap
$7.31M
Enterprise Value$519.24K
Total Cash (Recent Filing)$3.95M
Total Debt (Recent Filing)$173.00K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,906,479
10 Day Avg. Volume290,321
30 Day Avg. Volume393,928
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $2.78 and its highest was $446.00 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $7.31M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Nov 13, 2025 which is in 41 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Aug 20, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 1,906,479 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 6.431%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical company focused on developing novel oncology treatment options to improve the lives of patients with cancer. The company is headquartered in Edinburgh, Scotland, and primarily operates in the biotechnology and pharmaceutical sectors. NuCana leverages its proprietary ProTide technology platform to transform chemotherapeutic agents into more effective and safer medicines. Its lead product candidates are currently in various stages of clinical development, targeting a range of cancer types.
Technical Analysis
Ownership Overview
11.00%
Insiders
<0.01% Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---